Compare

Kairos Pharma/$KAPA

1D1W1M3M6MYTD1Y5YMAX

About Kairos Pharma

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
Ticker
$KAPA
Sector
Health
Primary listing
AMEX
Employees
-
Headquarters
Los Angeles, United States
Website
kairospharma.com

Kairos Pharma Metrics

BasicAdvanced
$1.7M
-
-$1.95
-
-

Kairos Pharma Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Kairos Pharma Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Kairos Pharma News

AllArticlesVideos

Kairos Pharma Presents at United Scientific Group's 11th International Conference on Cancer Research & Drug Development

Business Wire1 week ago

CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma

Newsfile Corp3 weeks ago

Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer

Benzinga1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.